Mammalian soluble epoxide hydrolase is identical to liver hepoxilin hydrolase

Journal of Lipid Research

Volumn 52, Issue 4, 2011, Pages 712-719

  Cronin, Annette ^a   Decker, Martina ^a   Arand, Michael ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

12 lipoxygenase; Eicosanoid; Lipid metabolism

Indexed keywords

EPOXIDE HYDROLASE; HEPOXILIN A; HEPOXILIN B; HEPOXILIN HYDROLASE; ICOSANOID; LIVER ENZYME; TRIOXILIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; HYDROLYSIS; LIVER HOMOGENATE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; BLOTTING, WESTERN; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EPOXIDE HYDROLASES; HUMANS; LIVER; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; RATS; TANDEM MASS SPECTROMETRY;

EID: 79953306229     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M009639     Document Type: Article

References (55)

1. Decker, M., M. Arand, and A. Cronin. 2009. Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. Arch. Toxicol. 83: 297-318.
2. Cronin, A., S. Homburg, H. Durk, I. Richter, M. Adamska, F. Frere, and M. Arand. 2008. Insights into the catalytic mechanism of human sEH phosphatase by site-directed mutagenesis and LC-MS/MS analysis. J. Mol. Biol. 383: 627-640.
3. Cronin, A., S. Mowbray, H. Durk, S. Homburg, I. Fleming, B. Fisslthaler, F. Oesch, and M. Arand. 2003. The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase. Proc. Natl. Acad. Sci. USA. 100: 1552-1557. (Pubitemid 36254485)
4. Newman, J. W., C. Morisseau, T. R. Harris, and B. D. Hammock. 2003. The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc. Natl. Acad. Sci. USA. 100: 1558-1563.
5. Enayetallah, A. E., R. A. French, M. S. Thibodeau, and D. F. Grant. 2004. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J. Histochem. Cytochem. 52: 447-454.
6. Sura, P., R. Sura, A. E. Enayetallah, and D. F. Grant. 2008. Distribution and expression of soluble epoxide hydrolase in human brain. J. Histochem. Cytochem. 56: 551-559.
7. Summerer, S., A. Hanano, S. Utsumi, M. Arand, F. Schuber, and E. Blee. 2002. Stereochemical features of the hydrolysis of 9,10-epoxystearic acid catalysed by plant and mammalian epoxide hydrolases. Biochem. J. 366: 471-480. (Pubitemid 35001691)
8. Zeldin, D. C., J. Kobayashi, J. R. Falck, B. S. Winder, B. D. Hammock, J. R. Snapper, and J. H. Capdevila. 1993. Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J. Biol. Chem. 268: 6402-6407.
9. Newman, J. W., C. Morisseau, and B. D. Hammock. 2005. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog. Lipid Res. 44: 1-51.
10. Fisslthaler, B., R. Popp, L. Kiss, M. Potente, D. R. Harder, I. Fleming, and R. Busse. 1999. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature. 401: 493-497. (Pubitemid 29470209)
11. Hu, S., and H. S. Kim. 1993. Activation of K+ channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid. Eur. J. Pharmacol. 230: 215-221.
12. Li, P. L., and W. B. Campbell. 1997. Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ. Res. 80: 877-884.
13. Imig, J. D., X. Zhao, J. H. Capdevila, C. Morisseau, and B. D. Hammock. 2002. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 39: 690-694.
14. Zhao, X., T. Yamamoto, J. W. Newman, I. H. Kim, T. Watanabe, B. D. Hammock, J. Stewart, J. S. Pollock, D. M. Pollock, and J. D. Imig. 2004. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J. Am. Soc. Nephrol. 15: 1244-1253.
15. Inceoglu, B., S. L. Jinks, K. R. Schmelzer, T. Waite, I. H. Kim, and B. D. Hammock. (2006) Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci. 79: 2311-2319.
16. Schmelzer, K. R., B. Inceoglu, L. Kubala, I. H. Kim, S. L. Jinks, J. P. Eiserich, and B. D. Hammock. 2006. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. USA. 103: 13646-13651.
17. Smith, K. R., K. E. Pinkerton, T. Watanabe, T. L. Pedersen, S. J. Ma, and B. D. Hammock. 2005. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc. Natl. Acad. Sci. USA. 102: 2186-2191.
18. Michaelis, U. R., B. Fisslthaler, E. Barbosa-Sicard, J. R. Falck, I. Fleming, and R. Busse. 2005. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J. Cell Sci. 118: 5489-5498. (Pubitemid 43079290)
19. Potente, M., B. Fisslthaler, R. Busse, and I. Fleming. 2003. 11,12-Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27Kip1. J. Biol. Chem. 278: 29619-29625. (Pubitemid 36962345)
20. Sun, J., X. Sui, J. A. Bradbury, D. C. Zeldin, M. S. Conte, and J. K. Liao. 2002. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ. Res. 90: 1020-1027.
21. Imig, J. D. 2005. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am. J. Physiol. Renal Physiol. 289: F496-F503. (Pubitemid 41208461)
22. Liu, Y., Y. Zhang, K. Schmelzer, T. S. Lee, X. Fang, Y. Zhu, A. A. Spector, S. Gill, C. Morisseau, B. D. Hammock, et al. 2005. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl. Acad. Sci. USA. 102: 16747-16752. (Pubitemid 41688848)
23. Schmelzer, K. R., L. Kubala, J. W. Newman, I. H. Kim, J. P. Eiserich, and B. D. Hammock. 2005. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl. Acad. Sci. USA. 102: 9772-9777.
24. Ohtoshi, K., H. Kaneto, K. Node, Y. Nakamura, T. Shiraiwa, M. Matsuhisa, and Y. Yamasaki. 2005. Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. Biochem. Biophys. Res. Commun. 331: 347-350. (Pubitemid 40545182)
25. Zhang, W., I. P. Koerner, R. Noppens, M. Grafe, H. J. Tsai, C. Morisseau, A. Luria, B. D. Hammock, J. R. Falck, and N. J. Alkayed. 2007. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J. Cereb. Blood Flow Metab. 27: 1931-1940.
26. Morisseau, C., J. W. Newman, H. J. Tsai, P. A. Baecker, and B. D. Hammock. 2006. Peptidyl-urea based inhibitors of soluble epoxide hydrolases. Bioorg. Med. Chem. Lett. 16: 5439-5444.
27. Morisseau, C., M. H. Goodrow, J. W. Newman, C. E. Wheelock, D. L. Dowdy, and B. D. Hammock. 2002. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem. Pharmacol. 63: 1599-1608.
28. Morisseau, C., and B. D. Hammock. 2005. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu. Rev. Pharmacol. Toxicol. 45: 311-333.
29. Arand, M., A. Cronin, F. Oesch, S. L. Mowbray, and T. A. Jones. 2003. The telltale structures of epoxide hydrolases. Drug Metab. Rev. 35: 365-383.
30. Pace-Asciak, C. R., and W. S. Lee. 1989. Purification of hepoxilin epoxide hydrolase from rat liver. J. Biol. Chem. 264: 9310-9313.
31. Nigam, S., M. P. Zafiriou, R. Deva, R. Ciccoli, and R. Roux-Van der Merwe. 2007. Structure, biochemistry and biology of hepoxilins: an update. FEBS J. 274: 3503-3512. (Pubitemid 47052415)
32. Laneuville, O., E. J. Corey, R. Couture, and C. R. Pace-Asciak. 1991. Hepoxilin A3 (HxA3) is formed by the rat aorta and is metabolized into HxA3-C, a glutathione conjugate. Biochim. Biophys. Acta. 1084: 60-68.
33. Pace-Asciak, C. R., and J. M. Martin. 1984. Hepoxilin, a new family of insulin secretagogues formed by intact rat pancreatic islets. Prostaglandins Leukot. Med. 16: 173-180.
34. Reynaud, D., P. M. Demin, M. Sutherland, S. Nigam, and C. R. Pace-Asciak. 1999. Hepoxilin signaling in intact human neutrophils: biphasic elevation of intracellular calcium by unesterified hepoxilin A3. FEBS Lett. 446: 236-238.
35. Derewlany, L. O., C. R. Pace-Asciak, and I. C. Radde. 1984. Hepoxilin A, hydroxyepoxide metabolite of arachidonic acid, stimulates transport of 45Ca across the guinea pig visceral yolk sac. Can. J. Physiol. Pharmacol. 62: 1466-1469.
36. Carlen, P. L., N. Gurevich, L. Zhang, P. H. Wu, D. Reynaud, and C. R. Pace-Asciak. 1994. Formation and electrophysiological actions of the arachidonic acid metabolites, hepoxilins, at nanomolar concentrations in rat hippocampal slices. Neuroscience. 58: 493-502.
37. Pace-Asciak, C. R., O. Laneuville, W. G. Su, E. J. Corey, N. Gurevich, P. Wu, and P. L. Carlen. 1990. A glutathione conjugate of hepoxilin A3: formation and action in the rat central nervous system. Proc. Natl. Acad. Sci. USA. 87: 3037-3041.
38. Anton, R., L. Puig, T. Esgleyes, J. M. de Moragas, and L. Vila. 1998. Occurrence of hepoxilins and trioxilins in psoriatic lesions. J. Invest. Dermatol. 110: 303-310. (Pubitemid 28158641)
39. Mrsny, R. J., A. T. Gewirtz, D. Siccardi, T. Savidge, B. P. Hurley, J. L. Madara, and B. A. McCormick. 2004. Identification of hepoxilin A3 in inflammatory events: a required role in neutrophil migration across intestinal epithelia. Proc. Natl. Acad. Sci. USA. 101: 7421-7426.
40. McCormick, B. A. 2007. Bacterial-induced hepoxilin A3 secretion as a pro-inflammatory mediator. FEBS J. 274: 3513-3518. (Pubitemid 47052416)
41. Brash, A. R., Z. Yu, W. E. Boeglin, and C. Schneider. 2007. The hepoxilin connection in the epidermis. FEBS J. 274: 3494-3502. (Pubitemid 47052414)
42. Laneuville, O., E. J. Corey, R. Couture, and C. R. Pace-Asciak. 1991. Hepoxilin A3 increases vascular permeability in the rat skin. Eicosanoids. 4: 95-97.
43. Epp, N., G. Furstenberger, K. Muller, S. de Juanes, M. Leitges, I. Hausser, F. Thieme, G. Liebisch, G. Schmitz, and P. Krieg. 2007. 12R-lipoxygenase deficiency disrupts epidermal barrier function. J. Cell Biol. 177: 173-182. (Pubitemid 46588410)
44. Yu, Z., C. Schneider, W. E. Boeglin, and A. R. Brash. 2007. Epidermal lipoxygenase products of the hepoxilin pathway selectively activate the nuclear receptor PPARalpha. Lipids. 42: 491-497.
45. Furstenberger, G., N. Epp, K. M. Eckl, H. C. Hennies, C. Jorgensen, P. Hallenborg, K. Kristiansen, and P. Krieg. 2007. Role of epidermis-type lipoxygenases for skin barrier function and adipocyte differentiation. Prostaglandins Other Lipid Mediat. 82: 128-134. (Pubitemid 44880166)
46. Yu, Z., C. Schneider, W. E. Boeglin, and A. R. Brash. 2005. Mutations associated with a congenital form of ichthyosis (NCIE) inactivate the epidermal lipoxygenases 12R-LOX and eLOX3. Biochim. Biophys. Acta. 1686: 238-247.
47. Sutherland, M., T. Schewe, and S. Nigam. 2000. Biological actions of the free acid of hepoxilin A3 on human neutrophils. Biochem. Pharmacol. 59: 435-440. (Pubitemid 30015973)
48. Reynaud, D., P. Demin, and C. R. Pace-Asciak. 1996. Hepoxilin A3-specific binding in human neutrophils. Biochem. J. 313: 537-541.
49. Nigam, S., S. Nodes, G. Cichon, E. J. Corey, and C. R. Pace-Asciak. 1990. Receptor-mediated action of hepoxilin A3 releases diacylglycerol and arachidonic acid from human neutrophils. Biochem. Biophys. Res. Commun. 171: 944-948.
50. Marowsky, A., J. Burgener, J. R. Falck, J. M. Fritschy, and M. Arand. 2009. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism. Neuroscience. 163: 646-661.
51. Sinal, C. J., M. Miyata, M. Tohkin, K. Nagata, J. R. Bend, and F. J. Gonzalez. 2000. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J. Biol. Chem. 275: 40504-40510.
52. Hwang, S. H., H. J. Tsai, J. Y. Liu, C. Morisseau, and B. D. Hammock. 2007. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J. Med. Chem. 50: 3825-3840.
53. Schladt, L., R. Hartmann, W. Worner, H. Thomas, and F. Oesch. 1988. Purification and characterization of rat-liver cytosolic epoxide hydrolase. Eur. J. Biochem. 176: 31-37.
54. Arand, M., M. Knehr, H. Thomas, H. D. Zeller, and F. Oesch. 1991. An impaired peroxisomal targeting sequence leading to an unusual bicompartmental distribution of cytosolic epoxide hydrolase. FEBS Lett. 294: 19-22.
55. Mullen, R. T., R. N. Trelease, H. Duerk, M. Arand, B. D. Hammock, F. Oesch, and D. F. Grant. 1999. Differential subcellular localization of endogenous and transfected soluble epoxide hydrolase in mammalian cells: evidence for isozyme variants. FEBS Lett. 445: 301-305.